Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L19-IL2 combined with stereotactic ablative body radiotherapy for oligometastatic solid tumors
NL-OMON44415Phase 1Active, not recruiting
- Sponsor
- Maastro Clinic
- Start
- Dec 2015
- Modality
- Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of darleukin in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and 3 more, sponsored by Maastro Clinic. Primary endpoint: Safety and tolerability. Started Dec 2015; status: active, not recruiting.
02
Drugs
darleukin
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)colorectal cancer (CRC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NL-OMON44415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44415.